In line with our observation in the GIST-RX1 model, in vitro tests in previous studies have demonstrated that regorafenib has modest growth inhibitory activity while sorafenib and sunitinib have little effect on GIST cell lines with the KIT exon 17 D816E secondary mutation [22, 23]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.